Investors Under Scrutiny: Pomerantz Law Firm Probes Sensus Healthcare for Possible Securities Fraud

Investor Alert: Pomerantz Law Firm Investigates Sensus Healthcare, Inc.

Pomerantz LLP has launched an investigation into Sensus Healthcare, Inc. (NASDAQ: SRTS) on behalf of its investors, following serious concerns regarding potential securities fraud and unlawful business practices by the company. This notice is particularly pertinent for shareholders who may have experienced losses, as Pomerantz seeks to uncover the truth behind these troubling claims.

The scrutiny comes after Sensus published its financial results for the second quarter of 2025, which revealed alarming figures. The company reported a GAAP earnings-per-share of -$0.06, trailing behind analysts' predictions by $0.09. This disappointing performance is further highlighted by a revenue drop to $7.3 million, a stark 20.7% year-over-year decline that also fell short of expectations by $2 million. Sensus attributed this downturn mainly to reduced sales to a significant customer, despite a boost in recurring revenue from Fair Deal Agreements.

On August 8, 2025, in response to these shocking disclosures, Sensus's stock fell sharply by $1.89, or 35.32%, closing at just $3.46 per share. This significant drop highlights a deepening crisis for the company and raises alarm bells among investors who are now questioning the integrity of Sensus's financial disclosures and business practices.

Pomerantz LLP, recognized as a leading firm in corporate and securities litigation, has a storied history of advocating for victims of corporate misconduct. Founded by the late Abraham L. Pomerantz, a pioneer in the field of class action lawsuits, the firm has dedicated itself to protecting shareholder rights for over 85 years. With offices located in major cities including New York, Chicago, and Tel Aviv, they are well-equipped to pursue justice on behalf of affected investors across borders.

Investors who believe they may have been misled by Sensus are encouraged to reach out to Pomerantz for assistance in joining any class action that may emerge from these investigations. Danielle Peyton, an attorney at Pomerantz, is the designated contact for inquiries related to the ongoing investigation and can be reached via email or by phone.

As the investigation unfolds, many investors will be anxiously awaiting further developments and the firm’s next steps in addressing these serious concerns. With a legacy of successful recoveries in similar cases, Pomerantz may provide a critical platform for affected investors to seek restitution for their losses.

Conclusion

The situation surrounding Sensus Healthcare remains fluid, and the ramifications of the recent financial disclosures are likely to be significant. As Sensus navigates this turbulent period, investor vigilance is essential. Staying informed and understanding one’s rights is indispensable, especially during such trying times in the market.

For those impacted by the events at Sensus, reaching out to knowledgeable legal representation such as Pomerantz LLP could provide essential support. Investors are urged to act swiftly, as actions taken now could determine the outcomes of potential legal recourse against the company.

For further inquiries, investors can contact Pomerantz LLP at the provided email and phone number to gather more insights and explore their options. Visit www.pomlaw.com for additional information.